Anti-Coagulants - Bahrain

Bahrain

In Bahrain, the Anti-Coagulants market is expected to achieve a revenue of US$4.75m by 2024.
The market is projected to grow at an annual growth rate (CAGR 2024-2029) of 7.53%, leading to a market volume of US$6.83m by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$16,740.00m in 2024.
Bahrain's increasing investment in healthcare infrastructure is fueling the demand for anti-coagulants in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Bahrain has seen a steady growth in recent years.

Customer preferences: Patients in Bahrain are increasingly looking for more effective and safer treatments for blood clots. Anti-Coagulants have become a popular choice due to their effectiveness in preventing blood clots and reducing the risk of stroke. Patients prefer oral anti-coagulants over injectable ones due to their ease of use and convenience.

Trends in the market: The Anti-Coagulants market in Bahrain is witnessing a shift from traditional blood thinners to newer oral anti-coagulants due to their better safety profile and ease of use. The market is expected to continue growing due to the rising prevalence of cardiovascular diseases and an aging population. Additionally, the increasing awareness about the benefits of anti-coagulants among healthcare professionals and patients is expected to drive the market growth.

Local special circumstances: Bahrain has a high prevalence of cardiovascular diseases, which is one of the major drivers of the Anti-Coagulants market. The country has a high incidence of risk factors such as obesity, diabetes, and hypertension, which increase the risk of blood clots and stroke. The government of Bahrain has taken several initiatives to promote healthy living and prevent cardiovascular diseases, which is expected to further drive the demand for anti-coagulants.

Underlying macroeconomic factors: Bahrain has a well-developed healthcare infrastructure and a high standard of medical care. The country has a high per capita income and a growing economy, which is expected to drive the demand for healthcare services, including anti-coagulants. Additionally, the government of Bahrain has been investing heavily in the healthcare sector, which is expected to further drive the growth of the Anti-Coagulants market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.